BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnston C, Koelle DM, Wald A. Current status and prospects for development of an HSV vaccine. Vaccine 2014;32:1553-60. [PMID: 24016811 DOI: 10.1016/j.vaccine.2013.08.066] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Sun S, Jin L, Zheng Y, Zhu J. Modeling human HSV infection via a vascularized immune-competent skin-on-chip platform. Nat Commun 2022;13:5481. [PMID: 36123328 DOI: 10.1038/s41467-022-33114-1] [Reference Citation Analysis]
2 Gui X, Zhang W, Gao P, Zhang Y, Zhou L, Ge X, Guo X, Wills JW, Han J, Yang H. Discovery and Characterization of an Aberrant Small Form of Glycoprotein I of Herpes Simplex Virus Type I in Cell Culture. Microbiol Spectr 2022;:e0265921. [PMID: 35348373 DOI: 10.1128/spectrum.02659-21] [Reference Citation Analysis]
3 Dorosti H, Eskandari S, Zarei M, Nezafat N, Ghasemi Y. Design of a multi-epitope protein vaccine against herpes simplex virus, human papillomavirus and Chlamydia trachomatis as the main causes of sexually transmitted diseases. Infect Genet Evol 2021;96:105136. [PMID: 34775078 DOI: 10.1016/j.meegid.2021.105136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Duan Q, Liu T, Huang C, Shao Q, Ma Y, Wang W, Liu T, Sun J, Fang J, Huang G, Chen Z. The Chinese Herbal Prescription JieZe-1 Inhibits Membrane Fusion and the Toll-like Receptor Signaling Pathway in a Genital Herpes Mouse Model. Front Pharmacol 2021;12:707695. [PMID: 34630083 DOI: 10.3389/fphar.2021.707695] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mhlanga A, Mushayabasa S. Computational and Theoretical Analysis of the Association Between Gender and HSV-2 Treatment Adherence. Acta Biotheor 2021;69:117-49. [PMID: 32880778 DOI: 10.1007/s10441-020-09392-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ayoub HH, Amara I, Awad SF, Omori R, Chemaitelly H, Abu-Raddad LJ. Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950-2050. Open Forum Infect Dis 2021;8:ofab218. [PMID: 34262986 DOI: 10.1093/ofid/ofab218] [Reference Citation Analysis]
7 Joyce JD, Patel AK, Murphy B, Carr DJJ, Gershburg E, Bertke AS. Assessment of Two Novel Live-Attenuated Vaccine Candidates for Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs. Vaccines (Basel) 2021;9:258. [PMID: 33805768 DOI: 10.3390/vaccines9030258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sergeyev OV, Bosh'ian RE, Barinsky IF. [RETRACTED: High-throughput sequencing in diagnostics and prevention of herpes simplex virus infection (Herpesviridae, Alphaherpesvirinae, Simplexvirus, Human alphaherpesvirus 1)]. Vopr Virusol 2020;65:126-31. [PMID: 33533214 DOI: 10.36233/0507-4088-2020-65-3-126-131] [Reference Citation Analysis]
10 Patel CD, Taylor SA, Mehrbach J, Awasthi S, Friedman HM, Leib DA. Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity. J Virol 2020;94:e02163-19. [PMID: 32188735 DOI: 10.1128/JVI.02163-19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
11 Treml J, Gazdová M, Šmejkal K, Šudomová M, Kubatka P, Hassan STS. Natural Products-Derived Chemicals: Breaking Barriers to Novel Anti-HSV Drug Development. Viruses 2020;12:E154. [PMID: 32013134 DOI: 10.3390/v12020154] [Cited by in Crossref: 15] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
12 Coates SJ, Leslie KS. What's new in HIV dermatology? F1000Res 2019;8:F1000 Faculty Rev-980. [PMID: 31297183 DOI: 10.12688/f1000research.16182.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
13 Reeves DB, Magaret AS, Greninger AL, Johnston C, Schiffer JT. Model-based estimation of superinfection prevalence from limited datasets. J R Soc Interface 2018;15:20170968. [PMID: 29491180 DOI: 10.1098/rsif.2017.0968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Ceña-Diez R, Martin-Moreno A, de la Mata FJ, Gómez-Ramirez R, Muñoz E, Ardoy M, Muñoz-Fernández MÁ. G1-S4 or G2-S16 carbosilane dendrimer in combination with Platycodin D as a promising vaginal microbicide candidate with contraceptive activity. Int J Nanomedicine 2019;14:2371-81. [PMID: 31040662 DOI: 10.2147/IJN.S188495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions. BMC Med 2019;17:57. [PMID: 30853029 DOI: 10.1186/s12916-019-1285-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
16 Pandey U, Szpara ML. Herpes Simplex Virus Disease Management and Diagnostics in the Era of High-Throughput Sequencing. Clin Microbiol Newsl 2019;41:41-8. [PMID: 34305220 DOI: 10.1016/j.clinmicnews.2019.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Çuburu N, Kim R, Guittard GC, Thompson CD, Day PM, Hamm DE, Pang YS, Graham BS, Lowy DR, Schiller JT. A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells. J Immunol 2019;202:1250-64. [PMID: 30635393 DOI: 10.4049/jimmunol.1800219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
18 Lo M, Zhu J, Hansen SG, Carroll T, Farr Zuend C, Nöel-Romas L, Ma ZM, Fritts L, Huang ML, Sun S, Huang Y, Koelle DM, Picker LJ, Burgener A, Corey L, Miller CJ. Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. J Virol 2019;93:e01574-18. [PMID: 30333177 DOI: 10.1128/JVI.01574-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bagdonaite I, Vakhrushev SY, Joshi HJ, Wandall HH. Viral glycoproteomes: technologies for characterization and outlook for vaccine design. FEBS Lett 2018;592:3898-920. [PMID: 29961944 DOI: 10.1002/1873-3468.13177] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
20 Schiffer JT, Gottlieb SL. Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development. Vaccine 2019;37:7363-71. [PMID: 28958807 DOI: 10.1016/j.vaccine.2017.09.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
21 Zhu Y, Yang Y, Guo J, Dai Y, Ye L, Qiu J, Zeng Z, Wu X, Xing Y, Long X, Wu X, Ye L, Wang S, Li H. Ex vivo 2D and 3D HSV-2 infection model using human normal vaginal epithelial cells. Oncotarget 2017;8:15267-82. [PMID: 28146426 DOI: 10.18632/oncotarget.14840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
22 Johnston C, Magaret A, Roychoudhury P, Greninger AL, Cheng A, Diem K, Fitzgibbon MP, Huang ML, Selke S, Lingappa JR, Celum C, Jerome KR, Wald A, Koelle DM. Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents. Virology 2017;510:90-8. [PMID: 28711653 DOI: 10.1016/j.virol.2017.06.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
23 Cairns TM, Ditto NT, Lou H, Brooks BD, Atanasiu D, Eisenberg RJ, Cohen GH. Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging. PLoS Pathog 2017;13:e1006430. [PMID: 28614387 DOI: 10.1371/journal.ppat.1006430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
24 Posavad CM, Zhao L, Dong L, Jin L, Stevens CE, Magaret AS, Johnston C, Wald A, Zhu J, Corey L, Koelle DM. Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. Mucosal Immunol 2017;10:1259-69. [PMID: 28051084 DOI: 10.1038/mi.2016.118] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
25 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 643] [Article Influence: 98.7] [Reference Citation Analysis]
26 Johnston C, Corey L. Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev 2016;29:149-61. [PMID: 26561565 DOI: 10.1128/CMR.00043-15] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 14.5] [Reference Citation Analysis]
27 Woestenberg PJ, Tjhie JH, de Melker HE, van der Klis FR, van Bergen JE, van der Sande MA, van Benthem BH. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. BMC Infect Dis 2016;16:364. [PMID: 27484304 DOI: 10.1186/s12879-016-1707-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
28 Ceña-Diez R, Vacas-Córdoba E, García-Broncano P, de la Mata FJ, Gómez R, Maly M, Muñoz-Fernández MÁ. Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action. Int J Nanomedicine 2016;11:2147-62. [PMID: 27274240 DOI: 10.2147/IJN.S95301] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
29 Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R. Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine 2016;34:2216-24. [PMID: 27002499 DOI: 10.1016/j.vaccine.2016.03.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
30 Ceña-díez R, Sepúlveda-crespo D, Maly M, Muñoz-fernández MA. Dendrimeric based microbicides against sexual transmitted infections associated to heparan sulfate. RSC Adv 2016;6:46755-64. [DOI: 10.1039/c6ra06969j] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
31 Diaz FM, Knipe DM. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus. Virology 2016;488:61-7. [PMID: 26609935 DOI: 10.1016/j.virol.2015.10.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
32 Odegard JM, Flynn PA, Campbell DJ, Robbins SH, Dong L, Wang K, Ter Meulen J, Cohen JI, Koelle DM. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine 2016;34:101-9. [PMID: 26571309 DOI: 10.1016/j.vaccine.2015.10.137] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
33 Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One 2015;10:e0140765. [PMID: 26510007 DOI: 10.1371/journal.pone.0140765] [Cited by in Crossref: 282] [Cited by in F6Publishing: 286] [Article Influence: 40.3] [Reference Citation Analysis]
34 Marć MA, Domínguez-Álvarez E, Gamazo C. Nucleic acid vaccination strategies against infectious diseases. Expert Opin Drug Deliv 2015;12:1851-65. [PMID: 26365499 DOI: 10.1517/17425247.2015.1077559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
35 Qi Y, Xu Y, Pan Y, Li S, Li B, Pan M, Zhang S, Li Y. Overexpression and purification of HSV-2 glycoprotein D in suspension CHO cells with serum-free medium and immunogenicity analysis: Overexpression and Purification of HSV-2 Glycoprotein D. Biotechnology and Applied Biochemistry 2016;63:312-9. [DOI: 10.1002/bab.1386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Stanfield B, Kousoulas KG. Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections. Curr Clin Microbiol Rep 2015;2:125-36. [PMID: 27114893 DOI: 10.1007/s40588-015-0020-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
37 Visalli RJ, Ziobrowski H, Badri KR, He JJ, Zhang X, Arumugam SR, Zhao H. Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2015;25:3168-71. [PMID: 26112446 DOI: 10.1016/j.bmcl.2015.05.099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
38 Voellmy R, Bloom DC, Vilaboa N. A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus. Expert Rev Vaccines 2015;14:637-51. [PMID: 25676927 DOI: 10.1586/14760584.2015.1013941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
39 Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One 2015;10:e114989. [PMID: 25608026 DOI: 10.1371/journal.pone.0114989] [Cited by in Crossref: 255] [Cited by in F6Publishing: 254] [Article Influence: 36.4] [Reference Citation Analysis]
40 Halford WP. Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines? Expert Rev Vaccines 2014;13:691-710. [PMID: 24837838 DOI: 10.1586/14760584.2014.910121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
41 Stanfield BA, Stahl J, Chouljenko VN, Subramanian R, Charles AS, Saied AA, Walker JD, Kousoulas KG. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. PLoS One 2014;9:e109890. [PMID: 25350288 DOI: 10.1371/journal.pone.0109890] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
42 Kuo T, Wang C, Badakhshan T, Chilukuri S, BenMohamed L. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine 2014;32:6733-45. [PMID: 25446827 DOI: 10.1016/j.vaccine.2014.10.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
43 Cairns TM, Huang ZY, Whitbeck JC, Ponce de Leon M, Lou H, Wald A, Krummenacher C, Eisenberg RJ, Cohen GH. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. J Virol 2014;88:12612-22. [PMID: 25142599 DOI: 10.1128/JVI.01930-14] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
44 Fruth U, Broutet N, Deal C, Dodet B, Meheus A. Vaccines for sexually transmitted infections: past, present and future. Vaccine 2014;32:1525-6. [PMID: 24480028 DOI: 10.1016/j.vaccine.2014.01.051] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine. 2014;32:1527-1535. [PMID: 24581979 DOI: 10.1016/j.vaccine.2013.07.087] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 9.5] [Reference Citation Analysis]
46 Broutet N, Fruth U, Deal C, Gottlieb SL, Rees H; participants of the 2013 STI Vaccine Technical Consultation. Vaccines against sexually transmitted infections: the way forward. Vaccine 2014;32:1630-7. [PMID: 24480024 DOI: 10.1016/j.vaccine.2014.01.053] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
47 Mhlanga A, Bhunu CP, Mushayabasa S. HSV-2 and Substance Abuse amongst Adolescents: Insights through Mathematical Modelling. Journal of Applied Mathematics 2014;2014:1-17. [DOI: 10.1155/2014/104819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]